Company Overview - Neurocrine is entering 2026 with significant enterprise-wide momentum, driven by an expanding and diversified portfolio [2] - The company is focused on delivering substantial data in 2027, particularly from Phase II and Phase III trials, marking the beginning of a sustained data flow for several years [2] Leadership Insights - Kyle Gano, CEO of Neurocrine, emphasizes the importance of 2026 as a pivotal year for the company [2] - The leadership is optimistic about the upcoming trials and the potential impact on the company's growth trajectory [2]